T. gondii, Schizophrenia, and other Psychiatric Disorders
Powerful evidence supports an association between the parasite Toxoplasma gondii and schizophrenia.
Risks of Marijuana
The combination of a large selection of products, poor labeling, and a lack of regulatory oversight in the states that have approved marijuana for recreational use has created a potentially dangerous situation for consumers, who receive little guidance regarding dosing.
Antipsychotics in Dementia: Quantifying the Mortality Risk
Antipsychotics are associated with an increase in mortality risk for patients with dementia. Alternative interventions should be considered first to treat agitation, aggression, and psychosis in this population
Schizophrenia Patients with Genetic Mutation Have Equal Response but More Serious Side Effects; Passage of Medical Marijuana Laws Does Not Increase Adolescent Use
Compromised Health in Schizophrenia: Venous Thromboembolism and Fractures
Patients with schizophrenia have an elevated risk of venous thromboembolism and fractures.
About the BTP Newsletter
Our subscribers say BTP is…
"Very relevant, practical, and thought-provoking."
"About the only thing left without drug ads...objective and balanced."
"Succinct, readable, clear, timely and relevant!"
"Well written and scientifically sound."
Originating at the Massachusetts General Hospital and Harvard Medical School, Biological Therapies in Psychiatry has been a trusted resource for physicians for over 30 years. Described as "influential" by the Atlantic Monthly, this concise, four-page, monthly newsletter provides up-to-date information about the rapidly expanding field of psychotropic medications and other biological treatments for mental disorders.
From his perspective as an editor, teacher, investigator, and clinician, Alan J. Gelenberg, M.D., reviews the widespread literatures of science and clinical practice. Dr. Gelenberg distills the material most relevant for a busy practitioner and presents it each month with a balance of scientific curiosity, healthy skepticism, and clinical experience.
Dr. Gelenberg is Professor and Interim Chair of Psychiatry at Penn State, Hershey. Since 1987, Dr. Gelenberg has been Editor-in-Chief of the Journal of Clinical Psychiatry, and he recently chaired the workgroup that revised the American Psychiatric Association's major depressive disorder guidelines. Dr. Gelenberg has been on the faculty of Harvard Medical School, MIT, and the University of Arizona and has written numerous scientific articles and book chapters on mood disorders, depression, and schizophrenia. He is listed in the Best Doctors in America and America's Top Doctors and received the 1997 Exemplary Psychiatrist Award of the National Alliance for the Mentally Ill.
We offer both print and online subscriptions. Our web site provides subscribers with 24-hour access to archives as well as current issues. In addition, Continuing Medical Education credit is available for reading BTP. You can earn up to 12.0 hours in category 1 credit by answering questions in the December issue about topics covered during the year.